Metachromatic leucodystrophy clinical, biological, and therapeutic aspects;La leucodystrophie métachromatique aspects clinique, biologique et thérapeutique

Annales de Biologie Clinique

Volumn 68, Issue 4, 2010, Pages 385-391

  Barboura, Ilhem ^a   Ferchichi, Salima ^a   Dandana, Azza ^a   Jaidane, Zaineb ^a   Khelifa, Souhaira Ben ^a   Chahed, Hinda ^a   Mansour, Rachida Ben ^a   Chebel, Saber ^b   Maire, Irène ^c   Miled, Abdelhedi ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c HÔPITAL DEBROUSSE   (France)

Author keywords

Arylsulfatase A; Metachromatic leukodystrophy; Neurological affect; Sulfatide

Indexed keywords

ANTICOAGULANT AGENT; BETA GLUCOSIDASE; CEREBROSIDE SULFATASE; SPHINGOLIPID; SULFATIDE; WARFARIN;

ARTICLE; BLINDNESS; ENZYMOLOGY; GAUCHER DISEASE; GENETICS; GENOTYPE; HUMAN; HYDROLYSIS; LIPIDOSIS; MENTAL DEFICIENCY; METABOLISM; METACHROMATIC LEUKODYSTROPHY; NEUROLOGIC DISEASE; PHENOTYPE;

ANTICOAGULANTS; BETA-GLUCOSIDASE; BLINDNESS; CEREBROSIDE-SULFATASE; GAUCHER DISEASE; GENOTYPE; HUMANS; HYDROLYSIS; LEUKODYSTROPHY, METACHROMATIC; MENTAL RETARDATION; NERVOUS SYSTEM DISEASES; PHENOTYPE; SPHINGOLIPIDOSES; SPHINGOLIPIDS; SULFOGLYCOSPHINGOLIPIDS; WARFARIN;

EID: 77955891584     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2010.0448     Document Type: Article

References (29)

1. Murray RK, Grannier DK, Mayes PA, Rodwell V. Précis de biochimie de Harper. 23e édition américaine. Laval: Presse de l'université, 1996.
2. Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW. The Metabolic and Molecular Bases of Inherited Diseases. In: Scriver CR, ed. New York: McGraw-Hill, 2001.
3. Métais P, Agneray J, Férard G, Fruchart J C, Jardillier J C, Revol A, et al. Biochimie clinique, Biochimie métabolique. Paris: Simep, 1980.
4. Cui Y, Colsch B, Afonso C, Bauman N, Tabet J C, Mallet JM, et al. Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urin metachromatic leukodystrophies. Glycoconjugate J 2008; 25: 147-155
5. Borel JP, Maquart FX, Gillery PH, Exposite M. Biochimie pour le clinicien; mécanismes moléculaires et chimiques à l'origine des maladies. Paris: Frison-Roche, 1999.
6. Von Figura K, Gieselmann J, Jaeken J. Metachromatic leukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and molecular bases ofinherited disease. New York: McGraw-Hill, 2001: 3695-3724
7. Maria BL, Deidrick KM, Moser H, Naidu S. Leukodystrophies: pathogenesis, diagnosis, strategies, therapies, and future research directions. J Child Neurol 2003; 18: 578-590
8. Lugowska A, Berger J, Tylki-Szyman'ska A, Löschl B, Molser B, Zobel M, et al. Molecular and phenotypic characteristics of metachromatic leukodystrophy patients from Poland. Clin Genet 2005; 68:48-54.
9. Deconinck N, Messaaoui A, Ziereisen F, Kadhim H, Sznajer Y, Pelc K, et al. Metachromatic leukodystrophy without arylsulfatase A deficiency: a new case of saposin-B deficiency. Eur JPaediatr Neurol 2008; 12: 46-50.
10. Bognar SK, Furac I, Kubat M, Cosovic C, Demarin V. Croatation population Data for arylsulfatase A pseudodeficiency-associated mutations in healthy subjects, and in patients with Alzheimer-type dementia and down syndrome. Arch Med Res 2002; 33: 473-477
11. . Kolodny EH, Fluharty L. Metachromatic leukodystrophy and multiple sulfatase deficiency: sulfatide lipidosis. In: Scriver CR, Beaudet AL, Sly WS, Vall D, eds. The metabolic and molecular bases ofinherited disease. New York: McGraw-Hill, 1995: 2693-2739
12. Turpin J C, Gray F, Baumann N. Leucodystrophies. Encyclopédie Médico-Chirurgicale, Neurologie. Paris: Elsevier, 1994: 17-076-D-10.
13. Maire I, Caillaud C, Froissart R, Vanier M. Diagnostic biologique et moléculaire des maladies de surcharge lysosomale. Atlas des maladies de surcharge lysosomales. VML, 2007. www.vml-asso.org.
14. Baumann N, Turpin J C, Lefever M, Colsch B. Motor and psycho- cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationship ? J Physiol 2002; 96: 301-306
15. Whitfield PD, Sharp PC, Johnson DW, Nelson P, Meikle PJ. Characterisation of urinary sulfatides in metachromatic leukodystrophy using electrospray ionisation-tandem masse spectrometry. Mol Genet Metab 2001; 73: 30-37
16. Diez-Roux G, Ballabio A. Sulfatases and human disease. Ann Rev Genomics Hum Genet 2005; 6: 355-379
17. Cesani M, Capotondo A, Plati T, Sergi LS, Fumagalli F, Roncarolo MG, et al. Charaterisation of new arylsulfatase A gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophy. Hum Mutat 2009; 30: 936-945
18. Schestag F, Yaghootfam A, Habetha M, Poeppel P, Dietz f, Klein RA, et al. The functional consequences of mis-sense mutations affecting an intra-molecular salt bridge in arylsulfatase A. Biochem J 2002; 367:499-504.
19. Lukatela G, Krauss N, Theis K, Selmer T, Gieselmann V, von Figura K, et al. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulphate ester hydrolysis. Biochem 1998; 11: 3654-3664
20. Clouter-Mackie MB, Gagnier L. Spectrum of mutations in the arylsulfatase A gene in a Canadian collection including two novel frameshift mutations, a ion (C488R) and an MLD mutation (R84) in cis with a pseudodeficiency allele. Mol Genet Metab 2003; 79: 91-98
21. Biffi A, Cesani M, Fumagalli F, Del Carro U, Baldoli C, Canale S, et al. Metachromatic leukodystrophy - mutation analysis provides further evidence of genotype-phenotype correlation. Clin Genet 2008; 74: 349-357
22. Colsch B, Afonso C, Turpin J C, Portoukalian J, Tabet J C, Baumann N. Sulfogalactosylceramides in motor and psycho-cognitive adult metachromatic leukodystrophy: relations between clinical, biochemical analysis and molecular aspects. Biochim Biophys Acta 2008; 1780: 434-440
23. Dubois G, Turpin J C, Baumann N. Absence of ASA activity in healthy father of metachromatic leukodystrophy (MLD) patient. N Eng J Med 1975; 293: 302.
24. Polten A, Fluharty AL, Fluharty CB, Kappler J, Von Figura K, Gieselmann V. Molecular basis of different forms of metachromatic leukodystrophy. N Engl JMed 1991; 324: 18-22.
25. Maire I. Diagnostic prénatal (DPN) des maladies héréditaires du métabolisme (MHM). Biotribune 2004; 12: 56-59
26. Krivit W, Saphiro E, Peters C, Lockman LA, Charnas L, Loes D, et al. Adult metachromatic leukodystrophy treated by bone marrow transplantation in 18 patients. SSIEM 39th Annual Symposium Pargue, Czech Republic, 4-7 september 2001. JInheri Dis 2001; 24: 103.
27. Dali C, Lund AM. thérapie enzymatique substitutive par intraveineuse pour la leukodystrophie metachromatique (MLD). Congrès "Annual Clinical Genetics Meeting", Tampa, Floride (USA), 25-29 mars 2009.
28. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009; 150: 293-300.
29. Consiglio A, Quattrini E, Martino S. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors correction of neuropathology and protection against learning impairment in affected mice. Nat Med 2000; 7: 310-316